Market research
NKB2.F TG Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7B
- Analyst target
- 59.88
- Dividend yield
- Not available
- Beta
- 1.67
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US88322Q1085
- Market cap
- 7B
- Analyst target
- 59.88
- Dividend yield
- Not available
- Beta
- 1.67
About
About TG Therapeutics, Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NKB2.F discussion.
5 years, 5 months ago
TG Therapeutics, Inc is currently in a long term downtrend where the price is trading 7.3% below its 200 day moving average.
From a valuation standpoint, the stock is 2678.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 36489.1.
TG Therapeutics, Inc's total revenue sank by 0.0% to $38K since the same quarter in the previous year.
Its net income has dropped by 122.9% to $-88M since the same quarter in the previous year.
Finally, its free cash flow fell by 71.5% to $-52M since the same quarter in the previous year.
Based on the above factors, TG Therapeutics, Inc gets an overall score of 0/5.